Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 5/20 | 0.46 |
| ▸ | ACVRL1 | P37023 | 8/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14888176 | 0.89 | ACVRL1 (0.46) | PIK3CDACVRL1FGFR1FGFR3 | |
| SCHEMBL5137764 | 0.85 | ACVRL1 (0.46) | PIK3CDACVRL1FGFR1FGFR3 | |
| SCHEMBL57703 | 0.85 | FGFR1 (0.48) | ACVRL1FGFR1MAP4K4 | |
| SCHEMBL14327080 | 0.84 | ACVRL1 (0.47) | PIK3CDACVRL1FGFR1MAP4K4 | |
| SCHEMBL27747195 | 0.80 | PIK3CD (0.48) | PIK3CDMAP4K4 | |
| SCHEMBL16011267 | 0.80 | ACVRL1 (0.62) | PIK3CDACVRL1FGFR1FGFR3MAP4K4 | |
| SCHEMBL59608 | 0.79 | ACVRL1 (0.64) | PIK3CDACVRL1FGFR1FGFR3 | |
| SCHEMBL56767 | 0.79 | ACVRL1 (0.58) | PIK3CDACVRL1MAP4K4 | |
| SCHEMBL58549 | 0.79 | HRH3 (0.44) | PIK3CDACVRL1FGFR1FGFR3L3MBTL1 | |
| SCHEMBL15212935 | 0.77 | ACVRL1 (0.37) | ACVRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040691-B2 | Hydroxymethylaryl-substituted pyrrolotriazines as ALK1 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-26 | — | — | US | disclosed |
| US-20140256718-A1 | HYDROXYMETHYLARYL-SUBSTITUTED PYRROLOTRIAZINES AS ALK1 INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-11 | — | — | US | disclosed |
| CN-101466710-B | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC | 2013-05-29 | — | — | CN | disclosed |
| EP-1957485-B1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2013-02-13 | — | — | EP | disclosed |
| EP-1957485-B1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2013-02-13 | — | — | EP | disclosed |
| US-8143393-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143393-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143393-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-8129379-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129379-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100179125-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100179125-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100179125-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER HEALTHCARE LLC | 2010-03-11 | — | — | US | disclosed |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER HEALTHCARE LLC | 2010-03-11 | — | — | US | disclosed |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER HEALTHCARE LLC | 2010-03-11 | — | — | US | disclosed |
| CN-101466710-A | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2009-06-24 | — | — | CN | disclosed |
| EP-1957485-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer Healthcare, LLC (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007064931-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007064931-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179125-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | CDK4, CDKL4, MKI67 | PIK3CD 529/4885ACVRL1 941/4885FGFR1 23/4885 |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | CDK4, CDKL4, MKI67 | PIK3CD 608/4885ACVRL1 963/4885FGFR1 22/4885 |
| US-20140256718-A1 | HYDROXYMETHYLARYL-SUBSTITUTED PYRROLOTRIAZINES AS ALK1 INHIBITORS | ALK, FLT1, ACVR1 | PIK3CD 834/4885ACVRL1 4/4885FGFR1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.